232 related articles for article (PubMed ID: 15526345)
1. Proteome analysis of human substantia nigra in Parkinson's disease.
Basso M; Giraudo S; Corpillo D; Bergamasco B; Lopiano L; Fasano M
Proteomics; 2004 Dec; 4(12):3943-52. PubMed ID: 15526345
[TBL] [Abstract][Full Text] [Related]
2. Low Levels of Prohibitin in Substantia Nigra Makes Dopaminergic Neurons Vulnerable in Parkinson's Disease.
Dutta D; Ali N; Banerjee E; Singh R; Naskar A; Paidi RK; Mohanakumar KP
Mol Neurobiol; 2018 Jan; 55(1):804-821. PubMed ID: 28062948
[TBL] [Abstract][Full Text] [Related]
3. Native DIGE proteomic analysis of mitochondria from substantia nigra and striatum during neuronal degeneration and its compensation in an animal model of early Parkinson's disease.
Kuter K; Kratochwil M; Marx SH; Hartwig S; Lehr S; Sugawa MD; Dencher NA
Arch Physiol Biochem; 2016 Dec; 122(5):238-256. PubMed ID: 27467289
[TBL] [Abstract][Full Text] [Related]
4. Proteomic Characterization of Synaptosomes from Human Substantia Nigra Indicates Altered Mitochondrial Translation in Parkinson's Disease.
Plum S; Eggers B; Helling S; Stepath M; Theiss C; Leite REP; Molina M; Grinberg LT; Riederer P; Gerlach M; May C; Marcus K
Cells; 2020 Dec; 9(12):. PubMed ID: 33276480
[TBL] [Abstract][Full Text] [Related]
5. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
[TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson's disease pathogenesis.
Licker V; Turck N; Kövari E; Burkhardt K; Côte M; Surini-Demiri M; Lobrinus JA; Sanchez JC; Burkhard PR
Proteomics; 2014 Mar; 14(6):784-94. PubMed ID: 24449343
[TBL] [Abstract][Full Text] [Related]
7. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
Damier P; Hirsch EC; Agid Y; Graybiel AM
Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
[TBL] [Abstract][Full Text] [Related]
8. Mass Spectrometry-Based Proteomics Analysis of Human Substantia Nigra From Parkinson's Disease Patients Identifies Multiple Pathways Potentially Involved in the Disease.
Jang Y; Pletnikova O; Troncoso JC; Pantelyat AY; Dawson TM; Rosenthal LS; Na CH
Mol Cell Proteomics; 2023 Jan; 22(1):100452. PubMed ID: 36423813
[TBL] [Abstract][Full Text] [Related]
9. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
[TBL] [Abstract][Full Text] [Related]
10. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
11. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
12. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
13. Proteomic profiling of the substantia nigra demonstrates CNDP2 overexpression in Parkinson's disease.
Licker V; Côte M; Lobrinus JA; Rodrigo N; Kövari E; Hochstrasser DF; Turck N; Sanchez JC; Burkhard PR
J Proteomics; 2012 Aug; 75(15):4656-67. PubMed ID: 22410244
[TBL] [Abstract][Full Text] [Related]
14. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease.
Duda J; Pötschke C; Liss B
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):156-178. PubMed ID: 26865375
[TBL] [Abstract][Full Text] [Related]
15. Can mesenchymal stem cells reduce vulnerability of dopaminergic neurons in the substantia nigra to oxidative insult in individuals at risk to Parkinson's disease?
Datta I; Bhonde R
Cell Biol Int; 2012 Jul; 36(7):617-24. PubMed ID: 22417707
[TBL] [Abstract][Full Text] [Related]
16. A proteomic approach in the study of an animal model of Parkinson's disease.
De Iuliis A; Grigoletto J; Recchia A; Giusti P; Arslan P
Clin Chim Acta; 2005 Jul; 357(2):202-9. PubMed ID: 15946658
[TBL] [Abstract][Full Text] [Related]
17. Differential proteomics analysis of mononuclear cells in cerebrospinal fluid of Parkinson's disease.
Xing L; Wang D; Wang L; Lan W; Pan S
Int J Clin Exp Pathol; 2015; 8(11):15462-6. PubMed ID: 26823915
[TBL] [Abstract][Full Text] [Related]
18. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
[TBL] [Abstract][Full Text] [Related]
19. Effect of siRNA-induced silencing of cellular prion protein on tyrosine hydroxylase expression in the substantia nigra of a rat model of Parkinson's disease.
Wang X; Yang HA; Wang XN; Du YF
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173342
[TBL] [Abstract][Full Text] [Related]
20. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry.
Damier P; Hirsch EC; Agid Y; Graybiel AM
Brain; 1999 Aug; 122 ( Pt 8)():1421-36. PubMed ID: 10430829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
